Search

El Memorial Sloan Kettering Cancer Center (MSK) se compromete no solo a brindar una atención excepcional para combatir el cáncer, sino también, a asegurar el acceso a la atención para todo aquel que lo necesite. Desafortunadamente, algunos pacientes (generalmente aquellos cuyo seguro ofrece una red de servicios muy reducida o aquellos que no están asegurados) se encuentran en problemas para afrontar la gran carga financiera que conlleva un diagnóstico de cáncer. MSK cuenta con un equipo especial que se asegura de que estos pacientes puedan recibir la atención que se merecen.

… Monday, February 27, 2023 El Memorial Sloan Kettering Cancer Center (MSK) se compromete no solo a brindar una atención excepcional para combatir el cáncer, sino también, a asegurar el acceso a la atención para todo aquel que lo necesite. Desafortunadamente, algunos pacientes (generalmente aquellos cuyo

A targeted approach being developed to treat certain cancers may also be effective for Alzheimer’s disease.

… Thursday, January 16, 2020 Summary Researchers find that a targeted approach being developed to treat certain cancers also appears to help rewire brain circuitry in Alzheimer’s disease. The body is presented with stressors throughout life. These stressors include genetic and environmental challenges

Results from a large phase III clinical trial unveiled at this year’s ASCO meeting identify an effective targeted therapy for a subset of people with pancreatic cancer.

… Sunday, June 2, 2019 Summary The results of a phase III trial presented on June 2 at the annual meeting of the American Society of Clinical Oncology (ASCO) show that a targeted drug called a PARP inhibitor benefits people with a BRCA mutation and pancreatic cancer that has spread. Pancreatic cancer that

Patients with high-grade epithelial ovarian cancer with recurrence after neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) had similar outcomes following secondary cytoreduction surgery (SCS) compared to patients with recurrence after primary debulking surgery (PDS), according to a retrospective study by Memorial Sloan Kettering Cancer Center (MSK) Team Ovary.

… Tuesday, September 5, 2023 Patients with high-grade epithelial  ovarian cancer with recurrence after neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) had similar outcomes following secondary cytoreduction surgery (SCS) compared to patients with recurrence after primary debulking

… Wednesday, March 5, 2025 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce a new community mural, “One Hundred Views,” by artist Naomi Reis. The inaugural MSK mural was created in collaboration with fifth-grade students from  P.S. 183 Robert L. Stevenson Elementary School , the neighboring

In a new study, MSK researchers looked at why glioblastoma brain tumors usually come back after treatment. Their findings suggest that a subset of cells — cancer stem cells — are able to evade current treatments because they are not actively dividing, and that these cells later form new tumors.

… Tuesday, January 11, 2022 Glioblastoma brain tumors are one of the most deadly forms of cancer, with a five-year survival rate of less than 10% for patients 45 and older. Even when the tumors look as if they have been fully removed, they almost always come back. Investigators who are part of Memorial

MSK studies presented at the 2022 American Association for Cancer Research meeting include updates on a targeted therapy for lung cancer, lab research on combining statins with a breast cancer drug, and a new tool for diagnosing blood cancer.

… Monday, April 11, 2022 Dozens of investigators from Memorial Sloan Kettering Cancer Center (MSK) shared their research at the 2022 American Association for Cancer Research (AACR) annual meeting, held April 8 to 13 in New Orleans. The studies presented included: A clinical trial that looked at the long-term

Collaboration will enhance innovation and the adoption of AI in translational research with the goal of improving patient care and outcomes.

… Monday, February 17, 2025 Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN) and Memorial Sloan Kettering Cancer Center (MSK), a leading global cancer center, today announced a collaboration harnessing the power of artificial intelligence (AI), high performance computing (HPC), and

New MSK research identifies a gene mutation associated with resistance to breast cancer treatment; reports encouraging results for expanding use of a new prostate cancer radiotherapy; determines the best radiation level for avoiding complications treating spinal tumors; and finds that proton therapy is effective against previously treated head and neck cancers.

… Tuesday, October 15, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) identifies a gene mutation associated with resistance to breast cancer treatment, as well as a possible strategy for overcoming the resistance; reports encouraging results for expanding use of a new prostate cancer

New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.

… Thursday, March 9, 2023 New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — a hub for basic science and translational research within MSK — offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial